Moderna Appoints Dr. David Berman as Chief Development Officer

Berman brings extensive experience in oncology and infectious disease development to Moderna's executive team.

Jan. 30, 2026 at 7:55am

Got story updates? Submit your updates here. ›

Moderna, Inc. announced that Dr. David Berman has been appointed as the Company's Chief Development Officer, effective March 2, 2026. Dr. Berman will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel. Dr. Jacqueline Miller will step down as Chief Medical Officer and member of the Executive Committee on the same date, but will remain as a consultant to assist with the transition.

Why it matters

Moderna is a leader in mRNA technology and is working to develop innovative treatments for cancer, rare diseases, and infectious diseases. Dr. Berman's extensive experience in oncology and infectious disease drug development will be crucial as Moderna continues to expand its pipeline of mRNA-based medicines.

The details

Over his two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics. He most recently served as EVP and Head of Research and Development at Immunocore, where he led the development and approval of the first T cell receptor therapeutic. Prior to Immunocore, Dr. Berman served as SVP and Head of AstraZeneca's Immuno-oncology (IO) franchise, and has also held senior development roles at Bristol-Myers Squibb.

  • Dr. Berman will start in his new role at Moderna on March 2, 2026.
  • Dr. Jacqueline Miller will step down as Chief Medical Officer and member of the Executive Committee on the same date.

The players

Moderna, Inc.

A pioneer and leader in the field of mRNA medicine, developing vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

Dr. David Berman

An experienced pharmaceutical executive who will join Moderna as the new Chief Development Officer.

Stéphane Bancel

The Chief Executive Officer of Moderna.

Dr. Jacqueline Miller

The current Chief Medical Officer of Moderna who will step down from her role.

Got photos? Submit your photos here. ›

What they’re saying

“David's leadership experience in oncology and infectious disease will be critical as we continue to invest and drive innovation across Moderna's pipeline.”

— Stéphane Bancel, Chief Executive Officer of Moderna

“I am honored to take on the role of Chief Development Officer at Moderna, a company at the forefront of transformative medical innovation.”

— Dr. David Berman

What’s next

Dr. Berman will officially join Moderna's executive team on March 2, 2026, taking over as Chief Development Officer from Dr. Jacqueline Miller.

The takeaway

Moderna's appointment of Dr. David Berman as Chief Development Officer demonstrates the company's commitment to advancing its mRNA platform and pipeline of innovative treatments for cancer, rare diseases, and infectious diseases. Dr. Berman's deep expertise in these areas will be invaluable as Moderna continues to drive progress and impact through its mRNA medicines.